$1.77+0.01 (+0.57%)
Innate Pharma S.A.
Innate Pharma S.A. in the Healthcare sector is trading at $1.77. Wall Street consensus targets $6.00 (4 analysts), implying a +239.0% move over the next 12 months. The stock is currently 33% below its 52-week high of $2.63, remaining 0.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials...
Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung
Analysts are now discussing an updated €8 price target for Innate Pharma, while the fair value estimate sits at €6.10 with no change to the underlying model. This shift is being framed around what both bullish and bearish voices see in the 2026 catalyst cluster, including funding needs and how upcoming oncology readouts could influence sentiment. As you read on, you will see how these moving pieces fit together and what to watch as the story develops. Stay updated as the Fair Value for Innate...
Innate Pharma SA (IPHA) progresses with key trials and partnerships while navigating financial hurdles and revenue drops.
Innate Pharma (NASDAQ:IPHA) outlined progress across its prioritized oncology pipeline and reviewed full-year 2025 financial results, emphasizing a streamlined strategy centered on three clinical programs: lacutamab, IPH4502, and monalizumab. Management also highlighted an AstraZeneca-partnered prog
Innate Pharma (IPHA) said Monday that the US Food and Drug Administration completed a review of its